Oxidized Phospholipids and Risk of Calcific Aortic Valve Disease: The Copenhagen General Population Study

Pia R. Kamstrup, Ming Yow Hung, Joseph L. Witztum, Sotirios Tsimikas, Børge G. Nordestgaard

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

OBJECTIVE—: Lipoprotein(a) is causally associated with calcific aortic valve disease (CAVD). Lipoprotein(a) carries proinflammatory and procalcific oxidized phospholipids (OxPL). We tested whether the CAVD risk is mediated by the content of OxPL on lipoprotein(a). APPROACH AND RESULTS—: A case–control study was performed within the Copenhagen General Population Study (n=87 980), including 725 CAVD cases (1977–2013) and 1413 controls free of cardiovascular disease. OxPL carried by apoB (apolipoprotein B-100; OxPL-apoB) or apolipoprotein(a) (OxPL-apo(a)) containing lipoproteins, lipoprotein(a) levels, LPA kringle IV type 2 repeat, and rs10455872 genetic variants were measured. OxPL-apoB and OxPL-apo(a) levels correlated with lipoprotein(a) levels among cases (r=0.75 and r=0.95; both P<0.001) and controls (r=0.65 and r=0.93; both P<0.001). OxPL-apoB levels associated with risk of CAVD with odds ratios of 1.2 (95% confidence interval [CI]:1.0–1.6) for 34th to 66th percentile levels, 1.6 (95% CI, 1.2–2.1) for 67th to 90th percentile levels, 2.0 (95% CI, 1.3–3.0) for 91st to 95th percentile levels, and 3.4 (95% CI, 2.1–5.5) for levels >95th percentile, versus levels <34th percentile (trend, P<0.001). Corresponding odds ratios for OxPL-apo(a) were 1.2 (95% CI, 1.0–1.5), 1.2(95% CI, 0.9–1.6), 2.1(95% CI, 1.4–3.1), and 2.9(95% CI, 1.9–4.5; trend, P<0.001) and were similar for lipoprotein(a). LPA genotypes associated with OxPL-apoB, OxPL-apo(a), and lipoprotein(a) levels and explained 34%, 46%, and 39%, respectively, of the total variation in levels. LPA genotypes associated with risk of AVS; a doubling in genetically determined OxPL-apoB, OxPL-apo(a), and lipoprotein(a) levels associated with odds ratio of CAVD of 1.18 (95% CI, 1.10–1.27), 1.09 (95% CI, 1.05–1.13), and 1.09 (95% CI, 1.05–1.14), respectively, comparable to the corresponding observational estimates of 1.27 (95% CI, 1.16–1.39), 1.13 (95% CI, 1.08–1.18), and 1.11 (95% CI, 1.06–1.17). CONCLUSIONS—: OxPL-apoB and OxPL-apo(a) are novel genetic and potentially causal risk factors for CAVD and may explain the association of lipoprotein(a) with CAVD.

Original languageEnglish
Pages (from-to)1570-1578
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume37
Issue number8
DOIs
Publication statusPublished - Aug 1 2017

Fingerprint

Aortic Diseases
Aortic Valve
Lipoprotein(a)
Phospholipids
Apolipoproteins B
Population
Odds Ratio
Genotype
Kringles
Apolipoprotein B-100
Apoprotein(a)
Lipoproteins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Oxidized Phospholipids and Risk of Calcific Aortic Valve Disease : The Copenhagen General Population Study. / Kamstrup, Pia R.; Hung, Ming Yow; Witztum, Joseph L.; Tsimikas, Sotirios; Nordestgaard, Børge G.

In: Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 37, No. 8, 01.08.2017, p. 1570-1578.

Research output: Contribution to journalArticle

Kamstrup, Pia R. ; Hung, Ming Yow ; Witztum, Joseph L. ; Tsimikas, Sotirios ; Nordestgaard, Børge G. / Oxidized Phospholipids and Risk of Calcific Aortic Valve Disease : The Copenhagen General Population Study. In: Arteriosclerosis, Thrombosis, and Vascular Biology. 2017 ; Vol. 37, No. 8. pp. 1570-1578.
@article{e971f7a1f4ec49e69a509a868b2a7c96,
title = "Oxidized Phospholipids and Risk of Calcific Aortic Valve Disease: The Copenhagen General Population Study",
abstract = "OBJECTIVE—: Lipoprotein(a) is causally associated with calcific aortic valve disease (CAVD). Lipoprotein(a) carries proinflammatory and procalcific oxidized phospholipids (OxPL). We tested whether the CAVD risk is mediated by the content of OxPL on lipoprotein(a). APPROACH AND RESULTS—: A case–control study was performed within the Copenhagen General Population Study (n=87 980), including 725 CAVD cases (1977–2013) and 1413 controls free of cardiovascular disease. OxPL carried by apoB (apolipoprotein B-100; OxPL-apoB) or apolipoprotein(a) (OxPL-apo(a)) containing lipoproteins, lipoprotein(a) levels, LPA kringle IV type 2 repeat, and rs10455872 genetic variants were measured. OxPL-apoB and OxPL-apo(a) levels correlated with lipoprotein(a) levels among cases (r=0.75 and r=0.95; both P<0.001) and controls (r=0.65 and r=0.93; both P<0.001). OxPL-apoB levels associated with risk of CAVD with odds ratios of 1.2 (95{\%} confidence interval [CI]:1.0–1.6) for 34th to 66th percentile levels, 1.6 (95{\%} CI, 1.2–2.1) for 67th to 90th percentile levels, 2.0 (95{\%} CI, 1.3–3.0) for 91st to 95th percentile levels, and 3.4 (95{\%} CI, 2.1–5.5) for levels >95th percentile, versus levels <34th percentile (trend, P<0.001). Corresponding odds ratios for OxPL-apo(a) were 1.2 (95{\%} CI, 1.0–1.5), 1.2(95{\%} CI, 0.9–1.6), 2.1(95{\%} CI, 1.4–3.1), and 2.9(95{\%} CI, 1.9–4.5; trend, P<0.001) and were similar for lipoprotein(a). LPA genotypes associated with OxPL-apoB, OxPL-apo(a), and lipoprotein(a) levels and explained 34{\%}, 46{\%}, and 39{\%}, respectively, of the total variation in levels. LPA genotypes associated with risk of AVS; a doubling in genetically determined OxPL-apoB, OxPL-apo(a), and lipoprotein(a) levels associated with odds ratio of CAVD of 1.18 (95{\%} CI, 1.10–1.27), 1.09 (95{\%} CI, 1.05–1.13), and 1.09 (95{\%} CI, 1.05–1.14), respectively, comparable to the corresponding observational estimates of 1.27 (95{\%} CI, 1.16–1.39), 1.13 (95{\%} CI, 1.08–1.18), and 1.11 (95{\%} CI, 1.06–1.17). CONCLUSIONS—: OxPL-apoB and OxPL-apo(a) are novel genetic and potentially causal risk factors for CAVD and may explain the association of lipoprotein(a) with CAVD.",
author = "Kamstrup, {Pia R.} and Hung, {Ming Yow} and Witztum, {Joseph L.} and Sotirios Tsimikas and Nordestgaard, {B{\o}rge G.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1161/ATVBAHA.116.308761",
language = "English",
volume = "37",
pages = "1570--1578",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Oxidized Phospholipids and Risk of Calcific Aortic Valve Disease

T2 - The Copenhagen General Population Study

AU - Kamstrup, Pia R.

AU - Hung, Ming Yow

AU - Witztum, Joseph L.

AU - Tsimikas, Sotirios

AU - Nordestgaard, Børge G.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - OBJECTIVE—: Lipoprotein(a) is causally associated with calcific aortic valve disease (CAVD). Lipoprotein(a) carries proinflammatory and procalcific oxidized phospholipids (OxPL). We tested whether the CAVD risk is mediated by the content of OxPL on lipoprotein(a). APPROACH AND RESULTS—: A case–control study was performed within the Copenhagen General Population Study (n=87 980), including 725 CAVD cases (1977–2013) and 1413 controls free of cardiovascular disease. OxPL carried by apoB (apolipoprotein B-100; OxPL-apoB) or apolipoprotein(a) (OxPL-apo(a)) containing lipoproteins, lipoprotein(a) levels, LPA kringle IV type 2 repeat, and rs10455872 genetic variants were measured. OxPL-apoB and OxPL-apo(a) levels correlated with lipoprotein(a) levels among cases (r=0.75 and r=0.95; both P<0.001) and controls (r=0.65 and r=0.93; both P<0.001). OxPL-apoB levels associated with risk of CAVD with odds ratios of 1.2 (95% confidence interval [CI]:1.0–1.6) for 34th to 66th percentile levels, 1.6 (95% CI, 1.2–2.1) for 67th to 90th percentile levels, 2.0 (95% CI, 1.3–3.0) for 91st to 95th percentile levels, and 3.4 (95% CI, 2.1–5.5) for levels >95th percentile, versus levels <34th percentile (trend, P<0.001). Corresponding odds ratios for OxPL-apo(a) were 1.2 (95% CI, 1.0–1.5), 1.2(95% CI, 0.9–1.6), 2.1(95% CI, 1.4–3.1), and 2.9(95% CI, 1.9–4.5; trend, P<0.001) and were similar for lipoprotein(a). LPA genotypes associated with OxPL-apoB, OxPL-apo(a), and lipoprotein(a) levels and explained 34%, 46%, and 39%, respectively, of the total variation in levels. LPA genotypes associated with risk of AVS; a doubling in genetically determined OxPL-apoB, OxPL-apo(a), and lipoprotein(a) levels associated with odds ratio of CAVD of 1.18 (95% CI, 1.10–1.27), 1.09 (95% CI, 1.05–1.13), and 1.09 (95% CI, 1.05–1.14), respectively, comparable to the corresponding observational estimates of 1.27 (95% CI, 1.16–1.39), 1.13 (95% CI, 1.08–1.18), and 1.11 (95% CI, 1.06–1.17). CONCLUSIONS—: OxPL-apoB and OxPL-apo(a) are novel genetic and potentially causal risk factors for CAVD and may explain the association of lipoprotein(a) with CAVD.

AB - OBJECTIVE—: Lipoprotein(a) is causally associated with calcific aortic valve disease (CAVD). Lipoprotein(a) carries proinflammatory and procalcific oxidized phospholipids (OxPL). We tested whether the CAVD risk is mediated by the content of OxPL on lipoprotein(a). APPROACH AND RESULTS—: A case–control study was performed within the Copenhagen General Population Study (n=87 980), including 725 CAVD cases (1977–2013) and 1413 controls free of cardiovascular disease. OxPL carried by apoB (apolipoprotein B-100; OxPL-apoB) or apolipoprotein(a) (OxPL-apo(a)) containing lipoproteins, lipoprotein(a) levels, LPA kringle IV type 2 repeat, and rs10455872 genetic variants were measured. OxPL-apoB and OxPL-apo(a) levels correlated with lipoprotein(a) levels among cases (r=0.75 and r=0.95; both P<0.001) and controls (r=0.65 and r=0.93; both P<0.001). OxPL-apoB levels associated with risk of CAVD with odds ratios of 1.2 (95% confidence interval [CI]:1.0–1.6) for 34th to 66th percentile levels, 1.6 (95% CI, 1.2–2.1) for 67th to 90th percentile levels, 2.0 (95% CI, 1.3–3.0) for 91st to 95th percentile levels, and 3.4 (95% CI, 2.1–5.5) for levels >95th percentile, versus levels <34th percentile (trend, P<0.001). Corresponding odds ratios for OxPL-apo(a) were 1.2 (95% CI, 1.0–1.5), 1.2(95% CI, 0.9–1.6), 2.1(95% CI, 1.4–3.1), and 2.9(95% CI, 1.9–4.5; trend, P<0.001) and were similar for lipoprotein(a). LPA genotypes associated with OxPL-apoB, OxPL-apo(a), and lipoprotein(a) levels and explained 34%, 46%, and 39%, respectively, of the total variation in levels. LPA genotypes associated with risk of AVS; a doubling in genetically determined OxPL-apoB, OxPL-apo(a), and lipoprotein(a) levels associated with odds ratio of CAVD of 1.18 (95% CI, 1.10–1.27), 1.09 (95% CI, 1.05–1.13), and 1.09 (95% CI, 1.05–1.14), respectively, comparable to the corresponding observational estimates of 1.27 (95% CI, 1.16–1.39), 1.13 (95% CI, 1.08–1.18), and 1.11 (95% CI, 1.06–1.17). CONCLUSIONS—: OxPL-apoB and OxPL-apo(a) are novel genetic and potentially causal risk factors for CAVD and may explain the association of lipoprotein(a) with CAVD.

UR - http://www.scopus.com/inward/record.url?scp=85020191330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020191330&partnerID=8YFLogxK

U2 - 10.1161/ATVBAHA.116.308761

DO - 10.1161/ATVBAHA.116.308761

M3 - Article

C2 - 28572160

AN - SCOPUS:85020191330

VL - 37

SP - 1570

EP - 1578

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 8

ER -